Articles On Imugene (ASX:IMU)

Imugene (IMU) receives a South Korea patent grant for its HER-Vaxx Immunotherapy The patent will protect the composition and method of the product to 2036 Importantly, South Korea is a selected country to conduct the nextHERIZON Phase 2 cl...

Imugene’s HER-Vaxx candidate is in development for the HER-2 positive gastric cancer market, a type of stomach cancer with increased levels of a growth-promoting protein known as HER-2.

2021 came with many ups and downs, both on and off the market, but these 5 ASX shares weathered the storm to come out on top. We’ve taken a look at the All Ordinaries Index (ASX: XAO) – the index often used to gauge the market’s performanc...

On 05 January 2022, the equity market of Australia closed in red as healthcare sector witnessed selling pressure during the session. On the same day, ASX Midcap50 fell by 0.63% and ASX 300 was down by 0.32%. ASX All Ordinaries moved down by...

The Pro Medicus Limited (ASX: PME) share price sunk almost 10% on Wednesday despite no news being released from the company for more than a month. At market close, the Pro Medicus share price was down 9.69% to $56.95 apiece. It may be pa...

Highlights Australian shares dropped 0.3% to 7565.8 as heavy losses by healthcare and technology stocks weighed on the market. Investors across the globe are worried about interest rates increases and a spike in Omicron cases. The glo...

Australian stocks flirted with record levels before fading to their second loss in nine sessions as the seasonal Santa rally flagged. The S&P/ASX 200 peaked 13 points short of an all-time high in the first ten minutes of trade, then...

After lifting 2% yesterday, the ASX 200 retreated 0.3% today driven by a selloff in tech stocks. The local index opened higher in the morning, inching closer to its all time high before losing momentum after the mid session break. The tech...

The S&P/ASX 200 climbed to within 13 points of a record before turning lower as the Santa rally lost momentum.   The benchmark hit 7620.2 in early trade, then faded to a mid-session deficit of 21 points or 0.27 per cent. The broader...

Today, the S&P/ASX 200 Index (ASX: XJO) cemented its second-highest level on record as it kicked off the New Year with a bang. At the end of the session, the benchmark index finished 1.95% higher at 7,589.8 points. ASX investors were...

The first trading day of 2022 saw the ASX 200 surging by 2% to its highest level since August. All eleven sectors were in the green, with the Energy sector rising by more than 3.4, and Mining up 2.2%. The Energy sector was buoyed by coal st...

The first session of 2022 delivered the share market’s strongest advance in more than a year. The S&P/ASX 200 jumped 145 points or 1.95 per cent to its biggest gain since November 2020. All 11 sectors advanced. Macquarie Group bec...

The benchmark ASX 200 was up by 2% on the first day of trading in 2022. The ASX Emerging Companies Index (XEC) also rose in step, up by 1.6%. All eleven ASX sectors finished higher, with the energy and mining sectors leading the pack. In en...

The share market flew to a four-month high after Wall Street ended its first session of 2022 at a record. The S&P/ASX 200 surged 107 points or 1.44 per cent by mid-session. The rally eclipsed Friday’s 69-point end-of-year profit-taki...

The Imugene Limited (ASX: IMU) share price is climbing today following a development in the company’s latest clinical trial. The biotech company announced it had completed another leg in its trial for the treatment of lung cancer. It has...

The price action of ASX biotech shares was nothing short of a mixed bag in 2021. Several of the majors underperformed the benchmark S&P/ASX 200 Pharmaceuticals & Biotechnology index (AXPBJD), whereas many small-cap names came thro...

The ASX 200 Health Index (XHJ) is trading higher by 0.30% at the time of writing, compared to the broader index which is also up by 0.87%. Imugene (ASX:IMU) is up by 8% this morning, after confirming that its immunotherapy candidate, PD1-Va...

Imugene (IMU) has completed the Phase 1a monotherapy dose escalation of PD1-Vaxx and will now go on to the combination dose escalation The PD1-Vaxx is a B-cell activating immunotherapy designed to treat tumours such as lung cancer The tria...

“Our Phase 1a trial has been open 12 months and I’m pleased with both the pace of development and the early responses seen. It’s particularly gratifying to have followed a patient in the trial for over 12 months where their tumour burden ha...

It was the last full trading session for the ASX in 2021, and the local benchmark index closed flattish, just 0.04% higher at 7,512. The move followed S&P 500’s 70th record close overnight, with the Dow Jones also hovering at all time h...

The Santa rally overcame a mid-session wobble to deliver investors a sixth straight rise and a 16-week closing high on the last full trading session of 2021. The S&P/ASX 200 rallied in the final hour to a slender gain of 3.6 points o...

The share market drifted lower amid signs of buyer fatigue following a five-session rally across the Christmas break. The S&P/ASX 200 inched to a 16-week high before rolling over. By mid-session, the Australian benchmark was off eigh...

Highlights The ASX 200 was trading 1.6 points up at 7,511.4 in early trade. As Asia markets closed in the red on Wednesday, European stock markets closed mixed. The utilities sector is the biggest laggard today, falling 1.3%. The...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

Highlights The ASX 200 advanced 0.1 per cent, or 9.8 points, to 7364.8  today. Asian shares were mostly higher, following the positive session of the Wall Street overnight. Bitcoin, the largest cryptocurrency by market value, has risen...

A strong tech-led rebound on Wall Street overnight wasn’t enough to provide a boost for the ASX 200. The local index finished Wednesday flattish, with Real Estate being the main laggard, falling by 1.3%. The property sector retreated as NAB...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

The S&P/ASX 200 Index (ASX: XJO) is having a decent day of trading on the markets this Tuesday so far, nicely countering yesterday’s shaky start to the trading week. At the time of writing, the ASX 200 is up a healthy 0.75% at 7,347 po...

The share market shrugged off weak leads and record Covid numbers in NSW as robust consumer confidence data suggested Australians were learning to live with omicron and the Prime Minister ruled out further lockdowns. The S&P/ASX 200...

The ASX 200 started Christmas week in the red today, down by 0.27%, as investors turned increasingly cautious around the societal ramifications of Omicron. PM Scott Morrison has just called for a snap cabinet meeting to deal with the latest...

Today, the S&P/ASX 200 Index (ASX: XJO) took a trip to the downside amid key data from the Reserve Bank of Australia (RBA). Once again, RBA governor Philip Lowe rejected forecasts that the central bank will look to raise rates next yea...

The Tech sector weighed heavily on the local index today and was down by more than 2.5%, dragging the ASX 200 lower by 0.70%. The fall came on the back of negative sentiment on the Nasdaq overnight, which fell by more than 1%. Investors hav...

The ASX 200 eked out a small Tuesday gain, as local stocks drifted sideways following a weak lead from Wall Street. There wasn’t much happening on the macro front to drive any sector much higher or lower, although a dicey trading update fro...

“Attaining the key Chinese patent is an important milestone. This adds to Imugene’s portfolio of B-cell immunotherapies, and this will protect them in one of the world’s largest HER-2 positive gastric cancer markets until 2036,” Imugene’s M...

“To achieve two INDs for our programs (OV and B Cell) concurrently is an outstanding result for the team," says MD.

The Imugene Limited (ASX: IMU) share price is on course to start the week with a gain. In early trade, the immuno-oncology company’s shares are up 4% to 53.5 cents. Why is the Imugene share price charging higher? The catalyst for the rise...

Imugene (IMU) receives US FDA Investigational New Drug (IND) approval for two new drug candidates The first approval gives Imugene permission to begin patient recruitment and dosing for the nextHERIZON study in advanced gastric cancer The...

Today, the S&P/ASX 200 Index (ASX: XJO) experienced a bumpy ride as it bounced between positive and negative. Unfortunately, it was on the negative side of the fence that the market decided to settle on by the end of the day. In specif...

The ASX 200 finished lower by 0.28% today, as investors turn cautious ahead of the Fed’s CPI release this Friday (US time). Overnight, US and EU markets rose following Pfizer’s announcement that three doses of its jab could protect against...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a solid gain. At the time of writing, the benchmark index is up 0.4% to 7,245.1 points. Four ASX shares that are climbing more than most today are listed below...

The Imugene Limited (ASX: IMU) share price is up today on the back of a positive cancer treatment update. Shares in the biopharma company are currently trading at 50 cents, up 5.26%. Let’s take a look at what’s going on at Imugene. Wha...

The ASX 200 Health Index (XHJ) is down by 0.80% at the time of writing, compared to the broader index which is down by 0.40%. The stock price of Neuren Pharmaceuticals (ASX:NEU) is up 100% this morning after the company announced its North...

Imugene (IMU) doses its second patient in the phase one clinical trial of its CHECKvacc drug candidate on patients with triple negative breast cancer (TNBC) The study aims to evaluate the safety and efficacy of the CHECKvacc drug when admi...

“We hope that in time, CHECKvacc provides an improved outcome for the many women who are diagnosed every year with TNBC,” says CEO and MD.

Shares in biopharma company Imugene Limited (ASX: IMU) are inching lower in afternoon trade and are now changing hands at 48.8 cents apiece, down 4.41%. Whilst there’s been no market-sensitive information from the company today, its shar...

In the December 2021 quarterly rebalance Imugene will be added to the S&P/ASX 200 Index and Archer Materials added to the S&P/ASX All Technology Index.